Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 04 - 13 tags : Cancer save search
Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics’ Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 Therapy
Published: 2021-04-13 (Crawled : 00:00) - globenewswire.com
GALT | $3.36 -0.59% -0.6% 150K
|
Health Technology
|
| O: 31.87%
H: 0.18%
C: -17.34%
immunotherapy phase 1 therapy cancer research phase 2 phase 3 galectin-3
U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer
Published: 2021-04-13 (Crawled : 22:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.32%
H: 1.19%
C: 0.68%
treatment fda cancer approval granted grant
Hematology/Oncology (Cancer) Approvals & Safety Notifications
Published: 2021-04-13 (Crawled : 18:40) - fda.gov
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.03%
H: 0.56%
C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.03%
H: 1.03%
C: 0.22%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.27%
H: 0.33%
C: 0.09%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -1.85%
H: 0.42%
C: -0.3%
YMAB | $14.97 -0.93% -0.94% 410K
|
Health Technology
|
| O: 0.55%
H: 5.75%
C: 4.16%
VSTM | $10.19 -6.0% -6.38% 67K
|
Health Technology
|
| O: -1.85%
H: 2.64%
C: 1.13%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.56%
H: 0.18%
C: -0.4%
RIGL | $1.06 -4.51% -4.72% 1.2M
|
Health Technology
|
| O: -1.66%
H: 9.58%
C: 5.07%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.2%
H: 1.83%
C: 0.66%
KPTI | $1.265 -8.33% -9.09% 1.3M
|
Health Technology
|
| O: 0.89%
H: 5.1%
C: 0.1%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.0%
H: 3.18%
C: 1.93%
ILMN | $116.64 -1.4% -1.41% 1.8M
|
Health Technology
|
| O: 0.87%
H: 0.47%
C: -2.11%
EXEL | $22.47 -1.75% -1.78% 2.6M
|
Health Technology
|
| O: -0.38%
H: 4.2%
C: 3.09%
EPZM | $1.47 -1.34% 0.0%
|
Health Technology
|
| O: 0.18%
H: 3.17%
C: 0.24%
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: 0.0%
H: 4.56%
C: 1.79%
BPMC | News | $88.9 0.59% 0.58% 730K
|
Health Technology
|
| O: 0.37%
H: 6.32%
C: 3.68%
BGNE | $131.94 0.06% 0.06% 130K
|
Health Technology
|
| O: 0.24%
H: 2.16%
C: -0.12%
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: 0.15%
H: 2.63%
C: -0.15%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.01%
H: 0.61%
C: -0.14%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.86%
H: 2.16%
C: 0.66%
AGIO | News | $29.43 1.38% 1.36% 550K
|
Health Technology
|
| O: 0.73%
H: 4.5%
C: 1.75%
cancer approval
Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
Published: 2021-04-13 (Crawled : 12:00) - biospace.com/
NVCR | $12.04 -0.08% -0.08% 1.4M
|
Health Technology
|
| O: 50.14%
H: 10.14%
C: -0.34%
lung cancer cancer phase 3 trial dmc recommendations decades
Zai Lab Partner Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
Published: 2021-04-13 (Crawled : 12:00) - globenewswire.com
ZLAB | News | $14.2 3.5% 3.38% 690K
|
Health Technology
|
| O: 13.59%
H: 7.76%
C: 7.53%
NVCR | $12.04 -0.08% -0.08% 1.4M
|
Health Technology
|
| O: 50.14%
H: 10.14%
C: -0.34%
lung cancer cancer phase 3 trial
BridgeBio Pharma, Inc. and Roswell Park Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Cancers
Published: 2021-04-13 (Crawled : 12:00) - globenewswire.com
BBIO | $24.98 0.0% 2M
|
Health Technology
|
| O: 0.43%
H: 2.42%
C: 0.76%
genetic collaboration cancer research therapy pharma
BridgeBio Pharma, Inc. and The Lundquist Institute Collaborate to Advance Treatments for Genetically Driven Conditions and Cancers
Published: 2021-04-13 (Crawled : 12:00) - biospace.com/
BBIO | $24.98 0.0% 2M
|
Health Technology
|
| O: 0.43%
H: 2.42%
C: 0.76%
treatment genetic cancer collaboration pharma
Innovent and Lilly Release Phase 3 Results of TYVYT® (Sintilimab Injection) as a Second-Line Treatment for Squamous Non-Small Cell Lung Cancer at AACR Annual Meeting 2021
Published: 2021-04-13 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.35%
H: 1.36%
C: 0.75%
treatment lung cancer injection results cancer phase 3
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.